Piramal Pharma Ltd (PPLPHARMA)
₹218.04
Mkt cap
₹28,520 Cr
P/E ratio
—
P/B
3.55
Div yield
0.07%
ROE
−3.83%
ROCE
2.52%
EPS (TTM)
—
Book value
₹61
52W range
133–219
Sector
Healthcare
Price history
Previous close
Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments (1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC). Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions [1] and various organic initiatives. In 2010 the Domestic formulations business was sold to Abott for $3.7 billion [2] and Diagnostic Services was sold to Super Religare Laboratories (SRL) [3]
NSE PPLPHARMABSE 543635
Health check
Mixed
ProfitabilityWeak
GrowthModerate
TechnicalsBullish
52-week range
−0.29% from high₹218
₹133+63.61% from low₹219
Current
₹218.04
Prev close
₹213.96
Day
+1.91%
Price performance
1D
+1.91%
1W
+1.70%
1M
+4.05%
3M
+29.12%
6M
+43.16%
1Y
+16.10%
YTD
+22.16%
Financials
Revenue, profit & margin
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,749 | 1,911 | 1,959 | 2,552 | 1,951 | 2,242 | 2,204 | 2,754 | 1,934 | 2,044 | 2,140 | 2,752 | 2,270 | |
| Expenses | 1,617 | 1,646 | 1,690 | 2,022 | 1,747 | 1,900 | 1,866 | 2,193 | 1,827 | 1,885 | 1,944 | 2,291 | 2,075 | |
| Operating Profit | 132 | 266 | 268 | 530 | 204 | 342 | 338 | 561 | 107 | 159 | 196 | 461 | 195 | |
| OPM % | 8% | 14% | 14% | 21% | 10% | 15% | 15% | 20% | 6% | 8% | 9% | 17% | 9% | |
| Other Income | 53 | 68 | 43 | 8 | 42 | 78 | 29 | 58 | 98 | 80 | 12 | -116 | 109 | |
| Interest | 119 | 110 | 106 | 114 | 107 | 108 | 103 | 104 | 86 | 82 | 89 | 83 | 88 | |
| Depreciation | 174 | 185 | 186 | 196 | 185 | 192 | 197 | 243 | 197 | 203 | 213 | 218 | 224 | |
| Profit before tax | -107 | 40 | 19 | 227 | -45 | 120 | 67 | 273 | -79 | -46 | -94 | 43 | -7 | |
| Tax % | -8% | 87% | 48% | 55% | 97% | 81% | 94% | 44% | 3% | 115% | 45% | 121% | 830% | |
| Net Profit | -99 | 5 | 10 | 101 | -89 | 23 | 4 | 154 | -82 | -99 | -136 | -9 | -69 | |
| EPS in Rs | -0.75 | 0.04 | 0.08 | 0.77 | -0.67 | 0.17 | 0.03 | 1.16 | -0.61 | -0.75 | -1.02 | -0.07 | -0.52 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +1.30% · closed higher next day 6 of last 16
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 28 Oct '23◦ | 30 Jan '24◦ | 10 May '24◦ | 26 Jul '24 | 23 Oct '24◦ | 28 Jan '25◦ | 14 May '25◦ | 28 Jul '25◦ | 5 Nov '25◦ | 29 Jan '26 | 28 Apr '26◦ | 29 Jul '26◦ |
| Earnings day | +3.19% | +3.78% | +2.49% | +0.13% | +17.36% | +9.49% | −4.76% | +0.62% | −0.54% | −0.18% | −2.63% | +0.53% |
| +1 day | +12.97% | −0.47% | −1.03% | +2.39% | +12.13% | +5.81% | −6.47% | −1.46% | −0.63% | +0.47% | −1.58% | −0.04% |
| +5 days | +17.30% | +0.25% | −0.63% | +4.79% | +23.16% | +3.88% | −5.81% | −5.29% | −3.28% | +3.01% | +11.71% | +6.42% |
| +15 days | +29.62% | −2.95% | −0.56% | +10.29% | +15.49% | −9.56% | −5.00% | −6.15% | −7.00% | +5.90% | +7.06% | +10.72% |
| +30 days | +36.81% | −14.06% | +6.18% | +30.69% | +18.81% | −7.65% | −8.24% | −2.05% | −16.91% | −9.19% | −0.38% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202634.80%Promoter
Promoters34.80%0.05
FIIs12.51%17.66
DIIs14.57%1.04
Public37.62%18.61
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| PPLPHARMA | ₹214.22 | — | 28,520 | 0.07% | −69 | +25.75% | 2,270 | +17.39% | 2.52% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Concall transcripts48
TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptApr 2026PPTApr 2026RECApr 2026TranscriptJan 2026PPTJan 2026TranscriptNov 2025PPTNov 2025TranscriptOct 2025PPTJul 2025RECJul 2025PPTJul 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptOct 2024PPTOct 2024PPTSep 2024TranscriptJul 2024PPTJul 2024
Credit ratings6
Announcements5
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - ESG Rating 3 Sep - NSE Sustainability assigned Piramal Pharma an ESG rating of 65 for FY2025-26, up64.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 26 AugSustainability Report Of Piramal Pharma Limited For The Financial Year 2025-26 24 Aug - Piramal Pharma released its FY2025-26 Sustainability Report on 24 August 2026.Announcement under Regulation 30 (LODR)-Acquisition 18 Aug - Piramal Pharma acquired 40.67% more in Yapan Bio for ₹76 crore, raising stake to 74%.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 18 Aug